fda tirzepatide shortage resolved says that the GLP-1 is over FDA Declares End to Tirzepatide

1% to 4.9%), myocardial ischemia, myocardial infarction (0.5% to 0.9%), peripheral ischemia (0.5% to 0.9%), peripheral edema (1% to 4.9%), pulmonary edema, and pulmonary embolism were reported in clinical trials and/or in postmarketing experience

OUP Academic Additional Trusted / Regulatory / Drug Status Sources Eli Lilly and Company What to Know About Retatrutide Lilly Investor Relations ClinicalTrials.gov Official U.S

Practical implications For patients who develop allodynia on one GLP-1 medication, switching to a different medication within the class (or to a different formulation of the same medication) is a reasonable strategy to try

Caution applies when combining multiple interventions simultaneously

Chronic inflammation